Biogen Inc. (BIIB)
- Previous Close
126.30 - Open
124.89 - Bid 125.67 x 400
- Ask 125.98 x 400
- Day's Range
123.97 - 126.19 - 52 Week Range
110.04 - 238.00 - Volume
812,226 - Avg. Volume
1,741,682 - Market Cap (intraday)
18.435B - Beta (5Y Monthly) 0.12
- PE Ratio (TTM)
12.43 - EPS (TTM)
10.12 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
171.95
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
www.biogen.com7,605
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BIIB
View More
Performance Overview: BIIB
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIIB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIIB
View MoreValuation Measures
Market Cap
18.43B
Enterprise Value
22.46B
Trailing P/E
12.43
Forward P/E
8.42
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.87
Price/Book (mrq)
1.09
Enterprise Value/Revenue
2.29
Enterprise Value/EBITDA
8.31
Financial Highlights
Profitability and Income Statement
Profit Margin
15.07%
Return on Assets (ttm)
5.43%
Return on Equity (ttm)
9.19%
Revenue (ttm)
9.82B
Net Income Avi to Common (ttm)
1.48B
Diluted EPS (ttm)
10.12
Balance Sheet and Cash Flow
Total Cash (mrq)
2.6B
Total Debt/Equity (mrq)
39.00%
Levered Free Cash Flow (ttm)
3.43B
Research Analysis: BIIB
View MoreResearch Reports: BIIB
View MoreLowering our EPS estimates for 2025 and 2026
Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for spinal muscular atrophy and AD. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,605 people, and is a component of the S&P 500.
RatingPrice TargetStocks are comfortably in the green at midday on Friday, led by a strong jobs
Stocks are comfortably in the green at midday on Friday, led by a strong jobs report and earnings reports that are often ahead of expectations. Guidance on the impact (or not) of tariffs remains the wild card. On the jobs front, the Bureau of Labor Statistics (BLS) reported that the U.S. economy generated 177,000 nonfarm jobs in April, above our near-consensus forecast of 130,000. March's payrolls were revised lower by 43,000 and February by 15,000. The April result and the revisions to past results raised the three-month average to 155,000 from 152,000. Nonfarm payrolls are one of the indicators that the National Bureau of Economic Research (NBER) says it watches closely in assessing whether the U.S. is in a recession.
Biogen Earnings: Leqembi Sales Steadily Climbing; Business Outlook Reiterated
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetBiogen Earnings: Guidance Slightly Disappointing, Fair Value Lowered on Reassessment of Leqembi
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice Target